Drug Trial Radar · NCT07179653
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II Clinical Trial to Evaluate the Efficacy and Safety of TVAX-008 Injection in Chronic Hepatitis B Patients
Last checked: Nov 20, 2026Latest source record: Sep 18, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
48
Planned (sponsor's estimate)
Start
Jan 22, 2025
Primary completion
Dec 2025
Study completion Dec 2026
Sponsor
- Lead sponsor
- Grand Theravac Life Sciences (Nanjing) Co., Ltd.Industry
- Sponsor type
- Industry
- Collaborators
- Nanfang Hospital, Southern Medical University; Sichuan Provincial People's Hospital; Meng Chao Hepatobiliary Hospital of Fujian Medical University; Ruijin Hospital
- First posted
- Sep 18, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The objective of this study was to evaluate the efficacy and safety of TVAX- 008 injection in a multicenter, randomized, double-blind, placebo-controlled, parallel-group phase II clinical trial in subjects with HBSAg levels of 0.05 to 100 IU/mL, including CHB patients previously treated with siRNA/ASO drugs and treatment-naive HBV infection.
Conditions
- HBV Infection
Interventions
TVAX-008Drug
TVAX-008
PlaceboDrug
Placebo
Primary outcomes
What the sponsor says the trial is designed to measure.
- HBsAg clearance rateTime frame: Week49
Locations
1 site in 1 country. Site status is shown where the registry gives one.
NanFang Hospital
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.